DI-045 Analysis of the use of intravenous inmunoglobulins

Autor: J González Chávez, I Martínez-Brocal Ogayar, M Gajardo Álvarez

Publikováno v: Drug information and pharmacotherapy.

Background The use of intravenous immunoglobulin (IVIg) may represent a therapeutic option with great economic impact in clinical situations where there might be other alternatives; it is therefore advisable to strictly follow the recommendations of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::866b7d4d0e3c6cd05b063df0b296070b
https://doi.org/10.1136/ejhpharm-2017-000640.292

CP-040 Switching to Tenofovir/Emtricitabine/Rilpivirine in HIV-1 patients previously treated with Tenofovir/Emtricitabine/Efavirenz

Autor: M Gajardo Álvarez, R Tamayo Bermejo, M Del Barrio Aranda, J González Chávez, A Linares Alarcón

Publikováno v: European Journal of Hospital Pharmacy. 22:A16.2-A16

Background The new combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) produces fewer adverse central nervous system effects, encouraging better adherence while being as effective as the tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV) combi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6586771440b25550283f7636dc2fa399
https://doi.org/10.1136/ejhpharm-2015-000639.38

[Dual therapy as an alternative treatment in HIV pretreated patients: experience in a tertiary hospital].

Autor: Yunquera-Romero L, Asensi-Díez R; Rocío Asensi Diez, Servicio de Farmacia. Hospital Regional Universitario de Málaga. Dirección: Avenida de Carlos Haya s/n. CP.29010. Málaga. Spain. rocio.asensi.sspa@juntadeandalucia.es., Gajardo-Álvarez M, Muñoz-Castillo I

Publikováno v: Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia [Rev Esp Quimioter] 2016 Feb; Vol. 29 (1), pp. 25-31. Date of Electronic Publication: 2016 Jan 26.